Business
Announcement of AGM and Publication of AR
Announcement of AGM and Publication of AR.
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nAnnouncement of AGM and\nPublication of Annual Report 2023\n \nLONDON and SALT LAKE CITY, UT October 30, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Annual General Meeting (\"AGM\") will be held in-person on 15 December 2023 at 15.30 p.m. (GMT) at 6 Stratton Street Mayfair, London W1J 8LD. \n \nIn addition, the Company's Annual Report for the year ended 30 June 2023 has now been published on the Company's website: https://investors.renalytix.com/financials-and-filings/annual-and-half-year-reports\n \nThe 2023 Annual Report will be posted to shareholders who have not consented to receive electronic communications. \n \nTo help with practical arrangements for the AGM, any Shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at [email protected] or by telephone at +44 (0)20 7933 8790.\n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n \n\n\n\n\nStifel (Nominated Adviser, Joint Broker)\n\n\nTel: 020 7710 7600\n\n\n\n\nAlex Price / Nicholas Moore / Nick Harland / Samira Essebiyea\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nInvestec Bank plc (Joint Broker)\n\n\nTel: 020 7597 4000\n\n\n\n\nGary Clarence / Shalin Bhamra\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: 07980 541 893 / 07407 804 654\n\n\n\n\n\n\n\n\n\n\n\n\nCapComm Partners\n\n\n\n\n\n\n\nPeter DeNardo\n\n\nTel: 415-389-6400 or [email protected]\n\n\n\n\n \nAbout Renalytix\nRenalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and re...